Colin Love

Dr. Love brings more than three decades of experience developing, manufacturing and launching biotechnology products. He currently is the Chief Operating Officer and a co-founder of Replimune, a biotechnology company developing oncolytic immunotherapies, where he has served since 2015. Since December 2014, he has provided consultancy support to a range of life science companies, from small gene therapy start-ups to large established biotechnology companies, including Amgen. From 2011 to 2014, Dr. Love was a Vice President of Clinical Operations at Amgen, where he was responsible for the two sites developing and manufacturing T-VEC, an oncolytic virus therapy approved by the FDA and EMA in 2015. Dr. Love was previously Senior Vice President of Product Development at BioVex Group, Inc., a privately-held biotechnology company developing T-VEC, from 2000 to 2011 until its acquisition by Amgen. Before joining BioVex, he held leadership positions in manufacturing and development at Celltech plc (now UCB Celltech) from 1992 to 2000 and led development teams for Medeva plc, Serono Diagnostics and Amersham International. Dr. Love holds a PhD in Biochemistry from the University of Glasgow.